<DOC>
	<DOCNO>NCT02222233</DOCNO>
	<brief_summary>To determine relative bioavailability single dose 200 mg BI 671800 HEA ( choline ) administer delayed release ( enteric coat ) tablet ; via EnterionTM capsule solution jejunum , ascend descend colon , particulate ascend colon</brief_summary>
	<brief_title>Relative Bioavailability BI 671800 HEA Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Healthy male subject 2 . Aged 2165 year 3 . Body Mass Index ( BMI ) 18.529.9 kg/m2 inclusive 4 . Subjects must demonstrate ability swallow empty size 000 capsule 5 . Must willing able participate whole study must provide write informed consent 1 . Participation clinical research study involve investigational drug dosage form within previous 3 month 2 . Subjects previously enrol study 3 . Subjects ever seek advice refer general practitioner counsellor abuse misuse alcohol , non medical drug , medicinal drug substance abuse e.g . solvent 4 . Subjects admit current previous use Class A drug opiates , cocaine , ecstasy , lysergic acid diethylamide ( LSD ) intravenous amphetamine ( Subjects admit occasional past use cannabis exclude long negative drug abuse test abstinent least 12 month ) 5 . Positive drug abuse test result 6 . Regular alcohol consumption &gt; 21 unit per week ( 1 Unit = Â½ pint beer , 25 mL shoot 40 % spirit 125 mL glass wine ) 7 . Current smoker smoke within last 6 month . A breath carbon monoxide read great 10 ppm screen 8 . Radiation exposure clinical trial , include present study , exclude background radiation include diagnostic Xrays medical exposure , exceed 5 millisievert ( mSv ) last twelve month 10 mSv last five year . No occupationally expose worker , define Ionising Radiation Regulations 1999 , shall participate study . 9 . Clinically significant abnormal biochemistry , haematology urinalysis judge Investigator , repeat alanine aminotransferase ( ALT ) , aspartame aminotransferase ( AST ) , gammaglutamyltransferase ( GGT ) , alkaline phosphatase ( ALP ) Total bilirubin upper limit normal ( ULN ) 10 . History gastrointestinal surgery ( exception appendectomy unless perform within previous 12 month ) 11 . History clinically significant disease cardiovascular , renal , hepatic , respiratory , central nervous system ( CNS ) , metabolic particularly gastrointestinal disease , especially peptic ulceration , gastrointestinal bleeding , ulcerative colitis , Crohn 's Disease Irritable Bowel Syndrome 12 . History adverse reaction allergy study drug excipients , e.g . lactose rescue medication ( specify Sponsor ) . If subject suffers hayfever must expect symptom study period 13 . Acute diarrhoea constipation 7 day predict first study day . If screening occurs &gt; 7 day first study day , criterion determine first study day . Diarrhoea define passage liquid faeces and/or stool frequency great three time per day . Constipation define failure open bowel frequently every day 14 . Donation blood significant blood loss within previous three month 15 . Presence nonremovable metal object metal plate , screw , etc , abdominal region body ( exception sterilisation clip ) 16 . Subjects exclude study consider Investigator risk transmitting , blood body fluid , agent responsible acquire immunodeficiency syndrome ( AIDS ) sexually transmit disease hepatitis 17 . Positive hepatitis B ( HBV ) , hepatitis C ( HCV ) HIV result 18 . Subjects receive prohibited medication describe Section 4.2 19 . Unwilling avoid excessive sunlight exposure 20 . Failure satisfy Investigator fitness participate reason 21 . Use drug might reasonably influence result trial prolong QT/QTc interval within 10 day prior administration trial , CYP2C8 substrates amiodarone , amodiaquine , paclitaxel , rosiglitazone , pioglitazone repaglinide CYP2C9 warfarin , tolbutamide , phenytoin , losartan , acenocoumarol within 1 month six half life ( whichever great ) 22 . A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) 23 . A history additional risk factor torsade de pointes ( e.g. , heart failure , hypokalaemia , family history Long QT Syndrome )</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>